gefitinib has been researched along with Long QT Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, BN; Jie, LJ; Li, GY; Li, YD; Lin, JL; Mao, L; Wang, Y; Xie, D; Xie, HB; Zhang, HQ; Zhang, YH; Zhou, FG; Zhou, TL | 1 |
| Abulimiti, B; Dong, X; Fu, Z; Jin, M; Maimaitituersun, G | 1 |
2 other study(ies) available for gefitinib and Long QT Syndrome
| Article | Year |
|---|---|
Mechanisms of gefitinib-induced QT prolongation.
Topics: Action Potentials; Animals; Electrocardiography; ERG1 Potassium Channel; Gefitinib; Guinea Pigs; Heart Ventricles; HEK293 Cells; Humans; Long QT Syndrome; Male; Myocardial Contraction; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channel Blockers | 2021 |
Gefitinib Increases the Incidence of QT Prolongation in Patients with Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Electrocardiography; Gefitinib; Humans; Hypertension; Incidence; Long QT Syndrome; Lung Neoplasms | 2023 |